Latest Octagon Capital Advisors LP Stock Portfolio
$636Million– No. of Holdings #44
Octagon Capital Advisors LP Performance:
2024 Q2: -15.62%YTD: -7.78%2023: 6.15%
Performance for 2024 Q2 is -15.62%, and YTD is -7.78%, and 2023 is 6.15%.
About Octagon Capital Advisors LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Octagon Capital Advisors LP reported an equity portfolio of $636.3 Millions as of 30 Jun, 2024.
The top stock holdings of Octagon Capital Advisors LP are APLS, , . The fund has invested 17.4% of it's portfolio in APELLIS PHARMACEUTICALS INC and 7.1% of portfolio in DIANTHUS THERAPEUTICS INC.
The fund managers got completely rid off ALPINE IMMUNE SCIENCES INC (ALPN), PERSPECTIVE THERAPEUTICS INC and CYTOKINETICS INC (CYTK) stocks. They significantly reduced their stock positions in ANNEXON INC (ANNX), NUVATION BIO INC (NUVB) and SILENCE THERAPEUTICS PLC. Octagon Capital Advisors LP opened new stock positions in PERSPECTIVE THERAPEUTICS INC, REGULUS THERAPEUTICS INC (RGLS) and ELEVATION ONCOLOGY INC (ELEV). The fund showed a lot of confidence in some stocks as they added substantially to AN2 THERAPEUTICS INC (ANTX), CENTURY THERAPEUTICS INC (IPSC) and ALLOVIR INC (ALVR).
The top stock holdings of Octagon Capital Advisors LP are APLS, , . The fund has invested 17.4% of it's portfolio in APELLIS PHARMACEUTICALS INC and 7.1% of portfolio in DIANTHUS THERAPEUTICS INC.
The fund managers got completely rid off ALPINE IMMUNE SCIENCES INC (ALPN), PERSPECTIVE THERAPEUTICS INC and CYTOKINETICS INC (CYTK) stocks. They significantly reduced their stock positions in ANNEXON INC (ANNX), NUVATION BIO INC (NUVB) and SILENCE THERAPEUTICS PLC. Octagon Capital Advisors LP opened new stock positions in PERSPECTIVE THERAPEUTICS INC, REGULUS THERAPEUTICS INC (RGLS) and ELEVATION ONCOLOGY INC (ELEV). The fund showed a lot of confidence in some stocks as they added substantially to AN2 THERAPEUTICS INC (ANTX), CENTURY THERAPEUTICS INC (IPSC) and ALLOVIR INC (ALVR).
Octagon Capital Advisors LP Equity Portfolio Value
Last Reported on: 14 Aug, 2024
Octagon Capital Advisors LP Annual Return Estimates Vs S&P 500
Our best estimate is that Octagon Capital Advisors LP made a return of -15.62% in the last quarter. In trailing 12 months, it's portfolio return was -11.53%.
New Buys
| Ticker | $ Bought |
|---|---|
| perspective therapeutics inc | 15,755,100 |
| regulus therapeutics inc | 7,610,710 |
| elevation oncology inc | 2,016,900 |
New stocks bought by Octagon Capital Advisors LP
Additions
| Ticker | % Inc. |
|---|---|
| an2 therapeutics inc | 191 |
| century therapeutics inc | 146 |
| allovir inc | 133 |
| structure therapeutics inc | 125 |
| terns pharmaceuticals inc | 118 |
| ventyx biosciences inc | 59.29 |
| taysha gene therapies inc | 50.9 |
| dianthus therapeutics inc | 26.51 |
Additions to existing portfolio by Octagon Capital Advisors LP
Reductions
| Ticker | % Reduced |
|---|---|
| annexon inc | -80.49 |
| nuvation bio inc | -68.61 |
| silence therapeutics plc | -44.13 |
| insmed inc | -42.96 |
| jasper therapeutics inc | -42.59 |
| verona pharma plc | -20.00 |
| akero therapeutics inc | -16.66 |
| tenaya therapeutics inc | -9.73 |
Octagon Capital Advisors LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| perspective therapeutics inc | -17,514,900 |
| veru inc | -2,660,380 |
| glycomimetics inc | -9,000,000 |
| alpine immune sciences inc | -49,205,100 |
| vincerx pharma inc | -5,060,000 |
| allogene therapeutics inc | -3,218,400 |
| atyr pharma inc | -1,365,000 |
| phathom pharmaceuticals inc | -4,832,100 |
Octagon Capital Advisors LP got rid off the above stocks
Sector Distribution
Octagon Capital Advisors LP has about 74.1% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 74.1 |
| Others | 25.9 |
Market Cap. Distribution
Octagon Capital Advisors LP has about 7.2% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 32.5 |
| UNALLOCATED | 26 |
| SMALL-CAP | 23.8 |
| MICRO-CAP | 9.8 |
| LARGE-CAP | 7.2 |
Stocks belong to which Index?
About 32.9% of the stocks held by Octagon Capital Advisors LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 67.1 |
| RUSSELL 2000 | 32.9 |
Octagon Capital Advisors LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Octagon Capital Advisors LP
Octagon Capital Advisors LP has 44 stocks in it's portfolio. About 64% of the portfolio is in top 10 stocks. APLS proved to be the most loss making stock for the portfolio. INSM was the most profitable stock for Octagon Capital Advisors LP last quarter.
Last Reported on: 14 Aug, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACET | adicet bio inc | 0.15 | 767,799 | 929,037 | unchanged | 0.00 | ||
| AKRO | akero therapeutics inc | 1.04 | 283,372 | 6,647,910 | reduced | -16.66 | ||
| ALLO | allogene therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALPN | alpine immune sciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALVR | allovir inc | 1.11 | 9,800,000 | 7,088,340 | added | 133 | ||
| ANAB | anaptysbio inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ANNX | annexon inc | 0.31 | 400,000 | 1,960,000 | reduced | -80.49 | ||
| ANTX | an2 therapeutics inc | 1.09 | 3,220,260 | 6,923,560 | added | 191 | ||
| APLS | apellis pharmaceuticals inc | 17.37 | 2,880,880 | 110,511,000 | added | 2.63 | ||
| ARWR | arrowhead pharmaceuticals in | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AUTL | autolus therapeutics plc | 0.10 | 176,000 | 612,480 | unchanged | 0.00 | ||
| AVTE | aerovate therapeutics inc | 0.12 | 465,440 | 772,630 | added | 15.3 | ||
| BBIO | bridgebio pharma inc | 2.75 | 690,000 | 17,477,700 | unchanged | 0.00 | ||
| CABA | cabaletta bio inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CNTA | centessa pharmaceuticals plc | 3.33 | 2,345,080 | 21,176,000 | added | 13.83 | ||
| CRBP | corbus pharmaceuticals hldgs | 3.47 | 488,000 | 22,082,000 | added | 20.49 | ||
| CYBN | cybin inc | 0.79 | 18,604,600 | 5,041,860 | unchanged | 0.00 | ||
| CYTK | cytokinetics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| DYN | dyne therapeutics inc | 6.55 | 1,180,800 | 41,670,400 | reduced | -5.00 | ||
| ELEV | elevation oncology inc | 0.32 | 747,000 | 2,016,900 | new | |||